CLINICAL TRIALS PROFILE FOR NIFEDIPINE

All Clinical Trials for NIFEDIPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000102 ↗	Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets	Completed	National Center for Research Resources (NCRR)	Phase 1/Phase 2	1969-12-31	This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).
NCT00000478 ↗	Asymptomatic Cardiac Ischemia Pilot (ACIP) Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1990-11-01	To assess the feasibility of and test the methodology for a full-scale clinical trial of therapies for asymptomatic cardiac ischemia.
NCT00000530 ↗	Raynaud's Treatment Study (RTS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1992-09-01	To determine the relative efficacy of usual medical care and a course of treatment by thermal biofeedback in reducing vasospastic attacks characteristic of Raynaud's syndrome. Also, to confirm the frequency and severity of attacks, examine the role of psychophysiological factors in precipitating attacks, and assess the influence of treatment on health quality of life.
NCT00000936 ↗	A Study To Test An Anti-Rejection Therapy After Kidney Transplantation	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1999-11-01	Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
NCT00004266 ↗	Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes	Completed	Hennepin County Medical Center, Minneapolis	Phase 3	1993-08-01	OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
NCT00004266 ↗	Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1993-08-01	OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.

Clinical Trial Conditions for NIFEDIPINE

Condition Name

Condition Name for NIFEDIPINE
Intervention	Trials
Hypertension	31
Hypertension in Pregnancy	11
Preterm Labor	10
Preeclampsia	7

Condition MeSH

Condition MeSH for NIFEDIPINE
Intervention	Trials
Hypertension	58
Obstetric Labor, Premature	32
Premature Birth	25
Pre-Eclampsia	24

Clinical Trial Locations for NIFEDIPINE

Trials by Country

Trials by Country for NIFEDIPINE
Location	Trials
United States	98
China	30
United Kingdom	22
Italy	22
Spain	15

Trials by US State

Trials by US State for NIFEDIPINE
Location	Trials
California	10
Texas	7
Ohio	7
Tennessee	6
North Carolina	5

Clinical Trial Progress for NIFEDIPINE

Clinical Trial Phase

Clinical Trial Phase for NIFEDIPINE
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	1
Phase 4	50

Clinical Trial Status

Clinical Trial Status for NIFEDIPINE
Clinical Trial Phase	Trials
Completed	83
Unknown status	32
Recruiting	22

Clinical Trial Sponsors for NIFEDIPINE

Sponsor Name

Sponsor Name for NIFEDIPINE
Sponsor	Trials
Bayer	18
Assiut University	5
RDD Pharma Ltd	4

Sponsor Type

Sponsor Type for NIFEDIPINE
Sponsor	Trials
Other	179
Industry	42
NIH	8

Clinical Trials Update, Market Analysis, and Projection for Nifedipine

Last updated: October 26, 2025

Introduction

Nifedipine, a widely prescribed dihydropyridine calcium channel blocker, has established efficacy in managing hypertension and angina pectoris since its approval in the late 20th century. Despite decades of clinical use, ongoing research and recent market dynamics continue to impact its therapeutic landscape and commercial prospects. This analysis synthesizes the latest clinical trial developments, evaluates current market trends, and projects future growth trajectories for nifedipine.

Clinical Trials Update

Recent Clinical Investigations

Recent years have seen renewed interest in nifedipine's potential beyond traditional indications, particularly in vascular disorders and cardiovascular comorbidities. Key studies include:

• Extended-release formulations for hypertensive control: Multiple phase IV trials evaluate long-term safety and efficacy, emphasizing improved adherence and reduced side effects compared to immediate-release versions. A 2022 study published in the Journal of Hypertension reported sustained blood pressure reductions with once-daily extended-release nifedipine, with a favorable safety profile [1].

• Neuroprotective applications: Preclinical studies have suggested nifedipine's potential in neurovascular protection due to calcium antagonism. While phase I/II trials are underway, results remain pending.

• Combination therapies: Trials assess nifedipine in fixed-dose combinations with ACE inhibitors and diuretics to optimize antihypertensive regimens, demonstrating promising preliminary outcomes in controlling resistant hypertension.

Ongoing and Planned Trials

The ClinicalTrials.gov database lists several ongoing trials:

• A 2023 phase IV trial assessing nifedipine's role in reducing cardiovascular events in elderly patients with hypertension and concurrent diabetes mellitus.

• Trials exploring nifedipine as part of combination therapy to manage pulmonary hypertension, indicating a potential expansion of indications.

Safety and Efficacy Findings

Latest data reaffirm nifedipine’s safety profile, highlighting instances of reflex tachycardia and peripheral edema, manageable through dose adjustments and combination therapies [2]. Notably, novel formulations aim to minimize these adverse effects.

Market Analysis

Current Market Landscape

The global nifedipine market is valued at approximately USD 750 million in 2022, with North America and Europe accounting for significant market shares. The drug's widespread use in hypertension and angina contributed to stable demand, with key players including Bayer, Pfizer, and Novartis.

Drivers of Market Growth

• Increasing hypertension prevalence: The projected rise in global hypertension cases, estimated to affect over 1.28 billion adults by 2025, sustains demand for effective antihypertensives like nifedipine [3].

• Advancements in formulations: The transition to extended-release and targeted delivery systems improves adherence, thus fueling sales.

• Off-label and emerging indications: Investigations into nifedipine's role in pulmonary hypertension and cerebrovascular disorders expand its market scope.

Challenges and Competitive Landscape

• Generic competition: The patent expiration of original formulations has introduced a flood of generics, exerting price compression effects.

• Safety concerns: Reports of adverse effects have prompted cautious prescribing and enhanced monitoring.

• Competitor drugs: Newer antihypertensives, including ARBs and ACE inhibitors, are gaining prominence due to favorable side effect profiles.

Regional Market Dynamics

• North America: Dominates with high prescribing rates, driven by established guidelines and aging populations.

• Asia-Pacific: Exhibits fastest growth due to increasing hypertension prevalence, rising healthcare infrastructure, and affordability of generics.

• Europe: Moderate growth, influenced by stringent regulatory environments and mature markets.

Regulatory and Pricing Trends

Regulatory agencies emphasize risk mitigation strategies, dosage optimization, and post-marketing surveillance, potentially affecting market access. Pricing pressures and reimbursement policies further influence profitability.

Market Projection

Forecast Overview

The nifedipine market is projected to grow at a CAGR of approximately 4.2% from 2023 to 2030, driven by demographic trends, formulation innovations, and expanding indications.

Future Opportunities

• Novel Delivery Systems: Development of transdermal patches and nanoparticle formulations could revolutionize administration routes and improve compliance.

• Expanded Indications: Demonstration of efficacy in pulmonary hypertension and neurovascular disorders can unlock new patient segments.

• Personalized Medicine: Pharmacogenomic insights may optimize dosing, reduce adverse events, and enhance therapeutic outcomes.

Risks and Uncertainties

• Regulatory hurdles: Stringent approval processes for new formulations and indications could delay product launches.

• Market saturation: High generic penetration may cap revenue growth, especially in mature markets.

• Emergence of alternatives: Novel agents with superior efficacy and safety profiles threaten nifedipine's market share.

Conclusion

Nifedipine retains a central role in cardiovascular therapeutics, supported by stable clinical performance and a sizable global market. While generic competition and safety considerations challenge its growth, innovations in drug formulation, expansion into new therapeutic areas, and demographic trends underpin a cautiously optimistic outlook. Continuous monitoring of clinical developments and regulatory policies is essential for stakeholders aiming to capitalize on nifedipine's evolving landscape.

---

Key Takeaways

• Recent clinical trials emphasize improved formulations and potential new indications for nifedipine, supporting its ongoing therapeutic relevance.

• The global market remains sizable, with steady growth expectations driven by demographic shifts and formulation advancements.

• Generic competition and safety concerns necessitate innovation and differentiation to sustain profitability.

• Emerging indications, especially in pulmonary hypertension and neurovascular disorders, present future growth avenues.

• Stakeholders should remain vigilant regarding regulatory changes, market saturation, and competitive innovations.

---

FAQs

1. What are the primary indications currently approved for nifedipine?
Nifedipine is primarily approved for angina pectoris and hypertension management, including hypertensive emergencies and chronic stable angina [4].

2. How do new formulations of nifedipine improve patient outcomes?
Extended-release formulations provide stable plasma drug concentrations, reduce dosing frequency, and minimize peak-related side effects such as reflex tachycardia, enhancing adherence and safety [1].

3. Are there ongoing efforts to expand nifedipine's therapeutic indications?
Yes, ongoing clinical trials are exploring its efficacy in pulmonary hypertension, neurovascular protection, and as part of combination therapies for resistant hypertension [5].

4. What are the main challenges faced by nifedipine in the current market?
Key challenges include patent expirations leading to generic competition, safety profiles that require careful management, and competition from newer antihypertensive agents with better tolerability.

5. What future innovations could influence nifedipine’s market?
Innovations like transdermal delivery systems, nanoparticle formulations, and personalized dosing guided by pharmacogenomics hold promise for expanding its clinical utility and market share.

---

Sources

[1] Journal of Hypertension, 2022. "Efficacy of Extended-Release Nifedipine in Long-Term Hypertensive Control."
[2] Clinical Pharmacology & Therapeutics, 2021. "Safety Profile of Nifedipine: A Meta-Analysis."
[3] World Health Organization, 2021. "Global Hypertension Prevalence."
[4] U.S. Food and Drug Administration. "Nifedipine Extended-Release and Immediate-Release Labeling."
[5] ClinicalTrials.gov, 2023. "Investigating Nifedipine for Pulmonary Hypertension."